Cardiovascular DiseasesNCT07324278
Hybrid Stroke Rehab With Mirror Priming
A study testing Mirror priming and Conventional therapy in people with Cardiovascular Diseases and Stroke, run by I-Shou University at 1 site in Taiwan.
Trial summary
This trial aims to examine the effects of enhanced mirror priming, overcoming the limitations of traditional mirror therapy, to achieve optimization and personalized intervention. Read more about this study
- Who is it for?
- Ages 20 to 80 years
- Conditions the study is for
- Cardiovascular Diseases, Stroke, Cerebrovascular Disorders
- What is being tested?
- Mirror priming and Conventional therapy
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 81 participants
- Where
- 1 siteTaiwan
- Study dates
- 2 Feb 2026to 31 Dec 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- A first-ever unilateral stroke ≥3 months
- Age between 20 and 80 years
- Baseline Fugl-Meyer Assessment Upper Extremity (FMA-UE) score ≥ 10
- No severe spasticity in any joints of the affected arm
- Ability to follow the instructions
- No participation in other studies during the study period
- Willingness to provide informed written consent.
Who cannot join
- Serious medical problems or poor physical conditions that might be detrimental to study participation.
- Received or planned botulinum toxin injections within 3 months prior to or during the trial
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Taiwan1 site, 1 recruiting
- Recruiting
E-Da Hospital
Kaohsiung City, Yanchao District, 82445
Yi-chun Li, PhD, +886-7-6151100 ext. 7514, joyjoyfish@gmail.com
About this study
Official title: Hybrid Stroke Rehabilitation With Mirror Priming
This trial aims to examine the effects of enhanced mirror priming, overcoming the limitations of traditional mirror therapy, to achieve optimization and personalized intervention.
- Conditions
- Cardiovascular Diseases, Stroke, Cerebrovascular Disorders
- Being tested
- Mirror priming, Conventional therapy
- Keywords
- Rehabilitation, Mirror Therapy
- Medical subject headings
- Cardiovascular Diseases, Stroke, Cerebrovascular Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mirror primingBehavioural
During the mirror priming process, the movement images of the participant's unaffected limb are mirrored to the affected side to provide visual feedback.
Conventional therapyBehavioural
Conventional therapy is individualized and may include impairment-oriented, shaping, or whole-task practice.
| Study group | Role | What they receive |
|---|---|---|
| High-dose enhanced mirror priming group | Experimental | Not described Receives: Behavioral: Mirror priming; Behavioral: Conventional therapy |
| Low-dose enhanced mirror priming group | Experimental | Not described Receives: Behavioral: Mirror priming; Behavioral: Conventional therapy |
| Active control group | Active comparator | Not described Receives: Behavioral: Conventional therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Fugl-Meyer Assessment
Measured: Baseline, 2 weeks, 4 weeks, and 3 months post-intervention.
Secondary outcomes (8)
Grip and pinch power
Measured: Baseline, 4 weeks, and 3 months post-intervention.
Revised Nottingham Sensory Assessment
Measured: Baseline, 4 weeks, and 3 months post-intervention.
Berg Balance Scale
Measured: Baseline, 4 weeks, and 3 months post-intervention.
Motor Activity Log
Measured: Baseline, 4 weeks, and 3 months post-intervention.
ABILHAND Questionnaire
Measured: Baseline, 4 weeks, and 3 months post-intervention.
Chedoke Arm and Hand Activity Inventory
Measured: Baseline, 4 weeks, and 3 months post-intervention.
Stroke Impact Scale
Measured: Baseline, 4 weeks, and 3 months post-intervention.
Stroke Self-Efficacy Questionnaire
Measured: Baseline, 4 weeks, and 3 months post-intervention.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jan 2026
- Study start2 Feb 2026
- Primary completion30 Sep 2030 (estimated)
- Study completion31 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiovascular DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 81 participants (estimated)
Sponsor and investigators
- Lead sponsor
- I-Shou University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yi-chun Li, I-Shou University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07324278
- Sponsor's protocol ID
- ISU-OT-Li-02
- Status last verified
- Aug 2026
- First submitted
- 23 Dec 2025
- Last updated
- 25 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Hybrid Stroke Rehabilitation With Mirror Priming
- ClinicalTrials.gov ID
- NCT07324278
- Acronym / sponsor ID
- ISU-OT-Li-02
- Conditions
- Cardiovascular Diseases, Stroke, Cerebrovascular Disorders
- Keywords
- Rehabilitation, Mirror Therapy
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 81 participants (estimated)
- Lead sponsor
- I-Shou UniversityUniversity, hospital or other
- Study start
- 2 Feb 2026 (actual)
- Primary completion
- 30 Sep 2030 (estimated)
- Study completion
- 31 Dec 2030 (estimated)
- First posted
- 7 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This trial aims to examine the effects of enhanced mirror priming, overcoming the limitations of traditional mirror therapy, to achieve optimization and personalized intervention.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| High-dose enhanced mirror priming group | Experimental | Behavioral: Mirror priming, Behavioral: Conventional therapy |
| Low-dose enhanced mirror priming group | Experimental | Behavioral: Mirror priming, Behavioral: Conventional therapy |
| Active control group | Active comparator | Behavioral: Conventional therapy |
Who may qualify
- Ages
- 20 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- A first-ever unilateral stroke ≥3 months
- Age between 20 and 80 years
- Baseline Fugl-Meyer Assessment Upper Extremity (FMA-UE) score ≥ 10
- No severe spasticity in any joints of the affected arm
- Ability to follow the instructions
Key exclusion criteria (2 listed)
- Serious medical problems or poor physical conditions that might be detrimental to study participation.
- Received or planned botulinum toxin injections within 3 months prior to or during the trial
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mirror primingDuring the mirror priming process, the movement images of the participant's unaffected limb are mirrored to the affected side to provide visual feedback. | Behavioural | High-dose enhanced mirror priming group, Low-dose enhanced mirror priming group |
| Conventional therapyConventional therapy is individualized and may include impairment-oriented, shaping, or whole-task practice. | Behavioural | Active control group, High-dose enhanced mirror priming group, Low-dose enhanced mirror priming group |
Primary outcome
Fugl-Meyer Assessment
Time frame: Baseline, 2 weeks, 4 weeks, and 3 months post-intervention.
8 secondary outcomes
Grip and pinch power
Time frame: Baseline, 4 weeks, and 3 months post-intervention.
Revised Nottingham Sensory Assessment
Time frame: Baseline, 4 weeks, and 3 months post-intervention.
Berg Balance Scale
Time frame: Baseline, 4 weeks, and 3 months post-intervention.
Motor Activity Log
Time frame: Baseline, 4 weeks, and 3 months post-intervention.
ABILHAND Questionnaire
Time frame: Baseline, 4 weeks, and 3 months post-intervention.
Chedoke Arm and Hand Activity Inventory
Time frame: Baseline, 4 weeks, and 3 months post-intervention.
Stroke Impact Scale
Time frame: Baseline, 4 weeks, and 3 months post-intervention.
Stroke Self-Efficacy Questionnaire
Time frame: Baseline, 4 weeks, and 3 months post-intervention.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Cardiovascular Diseases
Enrolling by invitationObservational study
Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART)
Heart Failure
Recruiting
Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe
Stroke, Acute
Active, not recruitingObservational study
REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure
Aortic Valve Stenosis
RecruitingPhase 1/2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
RecruitingPhase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Mirror priming and Conventional therapy in people with Cardiovascular Diseases and Stroke, run by I-Shou University at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 25 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yi-chun Li, PhD (+886-7-6151100 ext. 7514, joyjoyfish@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Fugl-Meyer Assessment (time frame: Baseline, 2 weeks, 4 weeks, and 3 months post-intervention.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Aug 2026.